gbt
receives
rare
impact
award
innovation
national
organization
rare
disorders
nord
development
voxelotor
tablets
south
san
francisco
globe
newswire
global
blood
therapeutics
gbt
nasdaq
gbt
announced
today
received
rare
impact
industry
innovation
national
organization
rare
disorders
nord
gbt
received
award
voxelotor
tablets
virtual
event
october
following
nord
annual
rare
disease
orphan
products
breakthrough
summit
discovered
developed
gbt
oxbryta
first
therapy
directly
inhibits
hemoglobin
polymerization
root
cause
sickling
destruction
red
blood
cells
sickle
cell
disease
scd
currently
approved
united
states
treat
scd
adults
adolescents
age
years
older
honored
receive
recognition
nord
developing
novel
therapeutics
meet
needs
sickle
cell
community
underserved
far
long
said
ted
love
president
ceo
gbt
true
winners
sickle
cell
disease
patients
families
available
treatment
options
look
forward
continuing
work
closely
healthcare
providers
patients
rare
disease
community
whose
partnership
integral
development
oxbryta
advance
shared
goal
making
difference
lives
people
devastating
inherited
nord
rare
impact
awards
celebrate
individuals
groups
companies
making
extraordinary
contributions
lives
rare
disease
patients
caregivers
nord
leading
independent
advocacy
organization
committed
identification
treatment
cure
rare
disorders
programs
education
advocacy
research
patient
services
addition
september
oxbryta
selected
national
xconomy
awards
breakthrough
drug
year
year
national
xconomy
awards
honor
top
individuals
companies
organizations
within
united
states
life
sciences
ecosystem
sickle
cell
disease
sickle
cell
disease
scd
affects
estimated
people
united
estimated
people
millions
people
throughout
world
particularly
among
whose
ancestors
also
affects
people
hispanic
south
asian
southern
european
middle
eastern
scd
lifelong
inherited
blood
disorder
impacts
hemoglobin
protein
carried
red
blood
cells
delivers
oxygen
tissues
organs
throughout
due
genetic
mutation
people
scd
form
abnormal
hemoglobin
known
sickle
hemoglobin
process
called
hemoglobin
polymerization
red
blood
cells
become
sickled
deoxygenated
sickling
process
causes
hemolytic
anemia
low
hemoglobin
due
red
blood
cell
destruction
blockages
capillaries
small
blood
vessels
impede
flow
blood
oxygen
throughout
body
diminished
oxygen
delivery
tissues
organs
lead
complications
including
stroke
irreversible
organ
voxelotor
tablets
oxbryta
voxelotor
oral
therapy
patients
sickle
cell
disease
scd
oxbryta
works
increasing
hemoglobin
affinity
oxygen
since
oxygenated
sickle
hemoglobin
polymerize
oxbryta
inhibits
sickle
hemoglobin
polymerization
resultant
sickling
destruction
red
blood
cells
addressing
hemolytic
anemia
improving
oxygen
delivery
throughout
body
gbt
believes
oxbryta
potential
modify
course
scd
november
oxbryta
received
food
drug
administration
fda
accelerated
approval
treatment
scd
adults
children
years
age
condition
accelerated
approval
gbt
continue
study
voxelotor
study
confirmatory
study
using
transcranial
doppler
tcd
flow
velocity
assess
ability
oxbryta
decrease
stroke
risk
children
years
age
recognition
critical
need
new
scd
treatments
fda
granted
oxbryta
breakthrough
therapy
fast
track
orphan
drug
rare
pediatric
disease
designations
treatment
patients
scd
european
medicines
agency
ema
included
oxbryta
priority
medicines
prime
program
european
commission
ec
designated
oxbryta
orphan
medicinal
product
treatment
patients
scd
gbt
plans
seek
regulatory
approvals
expand
potential
use
oxbryta
united
states
treatment
scd
children
age
years
treat
hemolytic
anemia
scd
people
age
years
older
europe
important
safety
information
oxbryta
taken
patient
allergic
reaction
voxelotor
ingredients
oxbryta
see
end
patient
leaflet
list
ingredients
oxbryta
oxbryta
cause
serious
side
effects
including
serious
allergic
reactions
patients
tell
healthcare
provider
get
emergency
medical
help
right
away
get
rash
hives
shortness
breath
swelling
face
patients
receiving
exchange
transfusions
talk
healthcare
provider
possible
difficulties
interpretation
certain
blood
tests
taking
oxbryta
common
side
effects
oxbryta
include
headache
diarrhea
stomach
abdominal
pain
nausea
tiredness
rash
fever
possible
side
effects
oxbryta
taking
oxbryta
patients
tell
healthcare
provider
medical
conditions
including
liver
problems
pregnant
plan
become
pregnant
known
oxbryta
harm
unborn
baby
breastfeeding
plan
breastfeed
known
oxbryta
pass
breastmilk
harm
baby
patients
breastfeed
treatment
oxbryta
least
weeks
last
dose
patients
tell
healthcare
provider
medicines
take
including
prescription
medicines
vitamins
herbal
supplements
medicines
may
affect
oxbryta
works
oxbryta
may
also
affect
medicines
work
patients
advised
call
doctor
medical
advice
side
effects
side
effects
reported
fda
side
effects
also
reported
global
blood
therapeutics
full
prescribing
information
oxbryta
available
global
blood
therapeutics
global
blood
therapeutics
gbt
biopharmaceutical
company
dedicated
discovery
development
delivery
treatments
provide
hope
underserved
patient
communities
founded
gbt
delivering
goal
transform
treatment
care
sickle
cell
disease
scd
lifelong
devastating
inherited
blood
disorder
company
introduced
voxelotor
first
treatment
directly
inhibits
sickle
hemoglobin
polymerization
root
cause
red
blood
cell
sickling
scd
gbt
also
advancing
pipeline
program
scd
inclacumab
inhibitor
development
address
pain
crises
associated
disease
addition
gbt
drug
discovery
teams
working
new
targets
develop
next
generation
treatments
scd
learn
please
visit
follow
company
twitter
references
centers
disease
control
prevention
website
sickle
cell
disease
scd
https
ncbddd
sicklecell
accessed
june
european
medicines
agency
https
en
medicines
human
accessed
june
national
heart
lung
blood
institute
website
sickle
cell
disease
https
accessed
august
rees
dc
et
al
lancet
kato
gj
et
al
nat
rev
dis
primers
kato
gj
et
al
j
clin
invest
caboot
jb
et
al
paediatr
respir
rev
oxbryta
voxelotor
tablets
prescribing
information
south
san
francisco
calif
global
blood
therapeutics
november
contact
steven
immergut
simmergut
